Working… Menu

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (MOVES-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02906020
Recruitment Status : Recruiting
First Posted : September 19, 2016
Last Update Posted : July 15, 2019
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:

Primary Objectives:

  • Part 1: To determine the safety and tolerability of GZ/SAR402671 administered orally, as compared to placebo in patients with early-stage Parkinson's disease (PD) carrying a GBA mutation or other pre-specified variants.
  • Part 2: To determine the efficacy of GZ/SAR402671 administered orally daily, as compared to placebo in patients with early-stage Parkinson's disease carrying a GBA mutation or other pre-specified variants.

Secondary Objectives:

Part 1:

  • To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR4027671 in plasma when administered in early-stage Parkinson's disease patients carrying a GBA mutation.
  • To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in early-stage Parkinson's disease patients carrying a GBA mutation.

Part 2:

  • To demonstrate overall safety and tolerability of GZ/SAR4027671 administered orally in early-stage Parkinson's disease patients carrying a GBA mutation as compared to placebo.
  • To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma and CSF as measured by glucosylceramide (GL-1) when administered in early-stage Parkinson's disease patients carrying a GBA mutation.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: GZ/SAR402671 Drug: Placebo Phase 2

Detailed Description:
The total study duration per subject in Part 2 will be approximately 170 weeks that will consist of 8.5 weeks of screening period, 52 weeks of treatment period, 104 weeks of follow-up period, and 6 weeks of post-treatment observation period. Part 1 maximal duration will be up to 48 weeks outside Japan, and up to 66 weeks in Japan.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 243 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.
Actual Study Start Date : December 15, 2016
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: GZ/SAR402671
Part 1: Increasing dose of GZ/SAR402671 will be administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) will be administered once per day.
Drug: GZ/SAR402671
Pharmaceutical form:capsule Route of administration: oral

Placebo Comparator: Placebo
A matching placebo for Parts 1 and 2 will be administered once per day.
Drug: Placebo
Pharmaceutical form:capsule Route of administration: oral

Primary Outcome Measures :
  1. Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part II and III score [ Time Frame: From baseline to Week 8, and at Week 52 ]

Secondary Outcome Measures :
  1. Change from baseline in Parkinson's Disease Cognitive Rating Scale [ Time Frame: From baseline to Week 52 ]
  2. Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part I, II, and III score [ Time Frame: From baseline to Week 52 ]
  3. Change from baseline in Hoehn and Yahr score [ Time Frame: From baseline to Week 52 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria :

  • Male and female adults with a diagnosis of PD and who are heterozygous carriers of a GBA mutation associated with PD.
  • Patients carrying known sequence variants associated with GBA-PD (such as E326K) must have rapid eye movement (REM) sleep behavior disorder (RBD) confirmed by historically documented polysomnography or by questionnaire.
  • Age ≥18 years to 80 years inclusive at the time of informed consent signing.
  • Has symptoms of PD ≥2 years.
  • Hoehn and Yahr (H and Y) stage of 2 or lower at baseline.
  • Stable medication regimen of PD drugs for at least 30 days (at least 60 days for rasagiline) prior to randomization.
  • The patient is willing to abstain from grapefruit containing products for 72 hours prior to administration of the first dose of GZ/SAR402671 and for duration of the entire treatment period (Periods 2 and 3).
  • Signed written consent.

Exclusion criteria:

  • Parkinsonism due to drug(s) or toxin(s).
  • Patients carrying mutations in genes other than GBA that have been associated with an increased risk for PD, specifically LRKK2 (G2019S).
  • Patients with Gaucher disease (GD), defined by the presence of 2 mutated GBA alleles.
  • Montreal Cognitive Assessment score <20 at Screening Visit.
  • Patients with prior surgical history of deep brain stimulation (DBS).
  • Patients with baseline brain MRI without contrast showing a structural abnormality that is a possible cause of their PD signs or symptoms.
  • Hepatic insufficiency with liver function tests (LFT) >2 times upper limit of normal at Screening Visit.
  • The patient has prior known positive result on any of the following tests: hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV 1 and anti-HIV 2 Ab). Patients with a positive hepatitis B surface antibody (HBsAb) test with a history of prior hepatitis B immunization are eligible if other criteria are met (ie, negative tests for : HBsAg, hepatitis B core antibody [HBcAb],and hepatitis C [HCVAb].
  • Renal insufficiency as defined by creatine >1.5 times normal at Screening Visit.
  • The patient has received strong or moderate inducers or inhibitors of CYP3A4 within 30 days or 5 half-lives prior to randomization, whichever is longer.
  • The patient has, according to World Health Organization (WHO) Grading, a cortical cataract > one-quarter the lens circumference (grade cortical catact-2 [COR-2]) or a posterior subcapsular cataract >2 mm (grade posterior subscapsular cataract [PSC-2]). Patient with nuclear cataracts will not be excluded.
  • The patient is currently receiving potentially cataractogenic medications, including chronic regimen (more frequently than every 2 weeks) of any dose or route of corticosteroids or any medication that can cause cataract or worsen the vision of patients with cataract (eg, glaucoma medications) according to the Prescribing Information.
  • If female, pregnancy (defined as positive beta-human chorionic gonadotrophin [Beta-HCG] blood test) or lactating or breast-feeding.
  • Any medical disorders that, in the opinion of the Investigator, could interfere with study-related procedures. This includes condition(s) that preclude the safe performance of routine lumbar punctures, such as prohibitive spinal diseases, bleeding diasthesis, or clinically significant coagulopathy or thrombocytopenia.
  • Current participation in another investigational interventional study.
  • Any medications specifically used for treating memory dysfunction, such as, but not limited to cholinesterase inhibitors or memantine, are prohibited.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02906020

Layout table for location contacts
Contact: For queries about study, contact (with site no. if available) 800-633-1610 ext 1 then #

  Hide Study Locations
Layout table for location information
United States, Arizona
Investigational Site Number 8400017 Recruiting
Scottsdale, Arizona, United States, 85258
Contact: Imaging EndPoints         
Investigational Site Number 8400011 Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Mayo Clinic - Scottsdale/Phoenix         
United States, California
Investigational Site Number 8400004 Recruiting
La Jolla, California, United States, 92093
Contact: Altman Clinical and Translational Research Institute         
Investigational Site Number 8400019 Recruiting
Palo Alto, California, United States, 94304
Contact: Stanford Neuroscience Health Center         
Investigational Site Number 8400013 Recruiting
Sunnyvale, California, United States, 94085
Contact: Parkinson's Institute and Clinical Center         
United States, Connecticut
Investigational Site Number 8400015 Recruiting
New Haven, Connecticut, United States, 06510
Contact: The Institute for Neurodegenerative Disorder         
United States, Florida
Investigational Site Number 8400008 Recruiting
Boca Raton, Florida, United States, 33486
Contact: PD and Movement of Boca Raton         
United States, Illinois
Investigational Site Number 8400016 Recruiting
Chicago, Illinois, United States, 60611
Contact: Northwestern University         
Investigational Site Number 8400005 Recruiting
Chicago, Illinois, United States, 60612-3854
Contact: Rush University Medical Center         
United States, Massachusetts
Investigational Site Number 8400014 Recruiting
Boston, Massachusetts, United States, 02114
Contact: Massachusetts General Hospital - Neurology Associates         
United States, New York
Investigational Site Number 8400018 Recruiting
New York, New York, United States, 10003
Contact: Mount Sinai Beth Israel         
Investigational Site Number 8400010 Recruiting
New York, New York, United States, 10016
Contact: Langone Medical Center, NYU School of Medicine         
Investigational Site Number 8400001 Recruiting
New York, New York, United States, 10032
Contact: Neurological Institute Columbia University Medical Cen         
United States, Oregon
Investigational Site Number 8400021 Recruiting
Portland, Oregon, United States, 97210
Contact: Legacy Health         
Investigational Site Number 8400020 Recruiting
Portland, Oregon, United States, 97225
Contact: Providence Neurological Specialties West         
Investigational Site Number 8400009 Recruiting
Portland, Oregon, United States, 97239
Contact: Oregon Health and Science University         
United States, Pennsylvania
Investigational Site Number 8400002 Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Pennsylvania Hospital, University of Pennsylvania         
United States, Virginia
Investigational Site Number 8400006 Recruiting
Fairfax, Virginia, United States, 22030
Contact: Inova Fairfax Medical Campus         
United States, Washington
Investigational Site Number 8400012 Recruiting
Kirkland, Washington, United States, 98034
Contact: Booth Gardner Parkinson's Care Center         
Investigational Site Number 0400001 Recruiting
Innsbruck, Austria, 6020
Investigational Site Number 1240001 Recruiting
Montreal, Canada, H3A 2B4
Investigational Site Number 1240002 Recruiting
Ottawa, Canada, K1Y 4E9
Investigational Site Number 1240003 Recruiting
Vancouver, Canada, V6T 2B5
Investigational Site Number 2500001 Recruiting
Paris Cedex 13, France, 75651
Investigational Site Number 2760002 Recruiting
Kiel, Germany, 24105
Investigational Site Number 2760001 Recruiting
Tübingen, Germany, 72076
Investigational Site Number 3000004 Recruiting
Athens, Greece
Investigational Site Number 3760002 Recruiting
Haifa, Israel, 31096
Investigational Site Number 3760003 Recruiting
Petah-Tikva, Israel, 49100
Investigational Site Number 3760001 Recruiting
Tel Aviv, Israel, 64239
Investigational Site Number 3760004 Recruiting
Tel Hashomer, Israel, 52621
Investigational Site Number 3800001 Recruiting
Catanzaro, Italy, 88100
Investigational Site Number 3800004 Recruiting
Milano, Italy, 20126
Investigational Site Number 3800003 Recruiting
Pavia, Italy, 27100
Investigational Site Number 3800006 Recruiting
Rozzano, Italy, 20089
Investigational Site Number 3800002 Recruiting
Salerno, Italy, 84131
Investigational Site Number 3920001 Recruiting
Bunkyo-Ku, Japan
Investigational Site Number 3920003 Recruiting
Kodaira-Shi, Japan
Investigational Site Number 3920002 Recruiting
Kyoto-Shi, Japan
Investigational Site Number 3920005 Recruiting
Nagoya-Shi, Japan
Investigational Site Number 3920004 Recruiting
Osaka-Shi, Japan
Investigational Site Number 5780001 Recruiting
Trondheim, Norway, 7006
Investigational Site Number 6200002 Recruiting
Coimbra, Portugal, 3000-075
Investigational Site Number 6200003 Recruiting
Torres Vedras, Portugal, 2560-280
Investigational Site Number 7020001 Recruiting
Singapore, Singapore, 169608
Investigational Site Number 7020002 Recruiting
Singapore, Singapore, 308433
Investigational Site Number 7240002 Recruiting
Barcelona, Spain, 08025
Investigational Site Number 7240001 Recruiting
Sevilla, Spain, 41013
Investigational Site Number 7520001 Recruiting
Stockholm, Sweden, 14186
Investigational Site Number 1580001 Recruiting
Taoyuan County, Taiwan, 33305
United Kingdom
Investigational Site Number 8260001 Recruiting
London, United Kingdom, NW1 2PG
Investigational Site Number 8260002 Recruiting
Oxford, United Kingdom, OX3 9DZ
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company Identifier: NCT02906020     History of Changes
Other Study ID Numbers: ACT14820
2016-000657-12 ( EudraCT Number )
U1111-1180-6918 ( Other Identifier: UTN )
First Posted: September 19, 2016    Key Record Dates
Last Update Posted: July 15, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Individual participant data (IPD) and supporting clinical documents are available for request at While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address:

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases